Advertisement

Comprehensive Therapy

, Volume 28, Issue 1, pp 50–61 | Cite as

Type 2 diabetes management: A comprehensive clinical review of oral medications

  • David M. Quillen
  • Louis Kuritzky
Original Article

Abstract

Diabetes is a major and growing health problem in the US. An incredible array of different oral medications is now on the market. Clinicians should understand all these new medications and in which clinical picture they will work best.

Keywords

Metformin Rosiglitazone Pioglitazone Acarbose Troglitazone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American Diabetes Association. Diabetes Facts and Figures. Online edition. Available at: http://www.diabetes.org/ada/facts.asp. Accessed 09/18/01.Google Scholar
  2. 2.
    US Department of Health and Human Services, Center for Disease Control and Prevention (CDC). Diabetes Surveillance, 1997, Division of Diabetes Translation, December 1997.Google Scholar
  3. 3.
    American Diabetes Association: clinical practice recommendations 1999. Diabetes Care. 1999;22(Suppl 1):S20–23.Google Scholar
  4. 4.
    Peters AL, Legorreta AP, Ossorio RC, Davidson MB. Quality of outpatient care provided to diabetic patients. Diabetes Care. 1996;19:601–606.PubMedCrossRefGoogle Scholar
  5. 5.
    Hiss RG. Barriers to care in non-insulin dependent diabetes mellitus. The Michigan experience. Ann Intern Med. 1996; 124:146–148.PubMedGoogle Scholar
  6. 6.
    Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853.Google Scholar
  7. 7.
    Samraj GPN, Quillen DM, Kuritzky L. Improving management of type 2 diabetes mellitus: 3. Sulfonylureas. Hosp Pract (Off Ed). 1999;34(12):129–134, 137, 140.Google Scholar
  8. 8.
    Bohannon NJV. Management of T2DM. Primary Care Rep. 1995, May 8:65–74.Google Scholar
  9. 9.
    Clinical Phamacology Online, Gold Standard Multimedia Inc. (http://www.gsm.com). Accessed 09/20/2001.Google Scholar
  10. 10.
    Quillen DM, Samraj GPN, Kuritzky L. Improving management of type 2 diabetes mellitus: 2. Biguanides. Hosp Pract (Off Ed). 1999;34(11):41–44.Google Scholar
  11. 11.
    Feinglos MN, Bethel MA. Treatment of type 2 diabetes mellitus. Med Clin North Am. 1998;82:757–790.PubMedCrossRefGoogle Scholar
  12. 12.
    Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs. 1999;58(Suppl 1):31–39.PubMedCrossRefGoogle Scholar
  13. 13.
    Hulisz DT, Bonfiglio MF, Murray RD. Metformin-associated lactic acidosis. J Am Board Fam Pract. 1998;11:233–236.PubMedGoogle Scholar
  14. 14.
    Lee AJ. Metformin in noninsulin-dependent diabetes mellitus. Pharmacotherapy. 1996;16:327–351.PubMedGoogle Scholar
  15. 15.
    Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type 2 diabetes: results of a double-blind, placebo-controlled, dose response trial. Am J Med. 1997;103:491–497.PubMedCrossRefGoogle Scholar
  16. 16.
    Plosker GL, Faulds D. Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs. 1999;57: 409–38.PubMedCrossRefGoogle Scholar
  17. 17.
    Samraj GPN, Kuritzky L, Quillen DM. Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones. Hosp Pract (Off Ed). 2000;35(1):123–124, 129–132.Google Scholar
  18. 18.
    Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histological hepatoxicity associated with troglitazone. Ann Intern Med. 1998;129:36–38.PubMedGoogle Scholar
  19. 19.
    Quillen DM, Kuritzky L, Samraj GPN. Improving management of type 2 diabetes mellitus: 4. Meglitinides. Hosp Pract (Off Ed). 1999;34(13):38–40.Google Scholar
  20. 20.
    Damsbo P, Clauson P, Marbury TC, Windfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care. 1999;22:789–794.PubMedCrossRefGoogle Scholar
  21. 21.
    Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care. 1999;22: 463–467.PubMedCrossRefGoogle Scholar
  22. 22.
    Moses R, Slobodnuik R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22: 119–124.PubMedCrossRefGoogle Scholar
  23. 23.
    Raskin P, Kennedy F, Woo V, Rajeev J, Mueller PG. A multicenter, randomized study of the therapeutic effect of repaglinide combined with troglitazone in subjects with type 2 diabetes [Poster session]. 59th Annual Scientific Sessions, American Diabetes Association, June 19–22, 1999, San Diego, CA.Google Scholar
  24. 24.
    Keilson L, Mather S, Walter YH Subramanian S, McLeod JF. Synergistic effects of Nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000;85:1081–1086.PubMedCrossRefGoogle Scholar
  25. 25.
    Kalbag JB, Walter YH, Nedelman JR, McLeod JF. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Diabetes Care. 2001;24:73–77.PubMedCrossRefGoogle Scholar
  26. 26.
    Kuritzky L, Samraj GPN, Quillen DM. Improving management of type 2 diabetes mellitus: 1. α-Glucosidase inhibitors. Hosp Pract (Off Ed). 1999;34(10):43–46.Google Scholar
  27. 27.
    Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab. 1998;83:1515–1522.PubMedCrossRefGoogle Scholar
  28. 28.
    Granberry MC, Fonseca VA: Insulin resistance syndrome: options for treatment. South Med J. 1999;92:2–15.PubMedGoogle Scholar
  29. 29.
    Ovall F, Bell DSH. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr Pract. 1998;4:146–147.Google Scholar
  30. 30.
    Keirse MJ. New perspectives for the effective treatment of preterm labor. Am J Obstet Gynecol. 1995;173:618–628.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2002

Authors and Affiliations

  • David M. Quillen
    • 1
  • Louis Kuritzky
    • 1
  1. 1.Department of Community Health and Family Practice University of FloridaCollege of Medicine Family Practice Medical GroupGainesvilleUSA

Personalised recommendations